Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma

被引：1
|
作者：
Zhang, Yue [1 ]
Wu, Shenhong [1 ]
机构：
[1] Stony Brook Univ Hosp, Div Hematol & Oncol, Stony Brook, NY USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
OPEN-LABEL; MULTICENTER; NIVOLUMAB;
D O I：
10.21037/tcr.2019.06.39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S585 / S588
页数：4
相关论文
共 50 条
  • [21] Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma
    Powles, Tom
    EUROPEAN UROLOGY, 2018, 74 (05) : 679 - 680
  • [22] Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma
    Soleimani, Maryam
    Nappi, Lucia
    Kollmannsberger, Christian
    FUTURE ONCOLOGY, 2020, 16 (36) : 3021 - 3034
  • [23] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Motzer, Robert J.
    Penkov, Konstantin
    Uemura, Hirotsugu
    Campbell, Matthew T.
    Kollmannsberger, Christian K.
    Lee, Jae-Lyun
    Venugopal, Balaji
    Van Den Eertwegh, Alfonsus
    Negrier, Sylvie
    Gurney, Howard
    Albiges, Laurence
    Berger, Raanan
    Haanen, John
    Rini, Brian I.
    Larkin, James
    Schmidinger, Manuela
    Sandner, Robin
    Wang, Jing
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma
    Klaassen, Zachary
    Satkunasivam, Raj
    Wallis, Christopher J. D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2581 - 2582
  • [25] Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
    Oya, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Eto, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1517 - S1518
  • [26] Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
    Choueiri, T. K.
    Motzer, R. J.
    Rini, B., I
    Haanen, J.
    Campbell, M. T.
    Venugopal, B.
    Kollmannsberger, C.
    Gravis-Mescam, G.
    Uemura, M.
    Lee, J. L.
    Grimm, M-O
    Gurney, H.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Pal, S. K.
    Wang, J.
    Mariani, M.
    Krishnaswami, S.
    Cislo, P.
    Chudnovsky, A.
    Fowst, C.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2020, 31 (08) : 1030 - 1039
  • [27] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Choueiri, Toni K.
    Rini, Brian I.
    Cosgriff, Thomas
    Miyake, Hideaki
    Vogelzang, Nicholas J.
    Kannourakis, George
    Mariani, Mariangela
    Chiruzzi, Chiara
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Atkins, Michael B.
    Schmidinger, Manuela
    Magazzu, Domenico
    Di Pietro, Alessandra
    Motzer, Robert J.
    BJU INTERNATIONAL, 2016, 118 : 29 - 30
  • [28] Efficacy and safety analysis of TACE plus sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
    Lu, Haohao
    Ye, Qing
    Zheng, Chuansheng
    Fan, Li
    Xia, Xiangwen
    BMC CANCER, 2023, 23 (01)
  • [29] KEYNOTE-426Axitinib plus Pembrolizumab vs. Sunitinib in der Erstlinientherapie des metastasierten NierenzellkarzinomsKEYNOTE-426Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
    J. Bedke
    V. Stühler
    Der Urologe, 2020, 59 (7): : 841 - 842
  • [30] Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
    Uekawa, Ayano
    Kurahashi, Ryoma
    Motoshima, Takanobu
    Murakami, Yoji
    Yatsuda, Junji
    Kamba, Tomomi
    UROLOGY CASE REPORTS, 2022, 45
12345